AZD7789 for Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new medicine called AZD7789 that helps the immune system fight advanced solid tumors by blocking proteins that hide cancer cells. It aims to see if the medicine is safe and effective for patients whose cancer has progressed despite other treatments.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use immunosuppressive medication within 14 days before starting the study. Also, you cannot have any concurrent cancer treatments like chemotherapy or radiotherapy while participating.
What data supports the effectiveness of the drug AZD7789 for cancer?
How does the drug AZD7789 differ from other cancer treatments?
AZD7789 is unique because it may combine the mechanisms of action from drugs like ZD1839, which inhibits the epidermal growth factor receptor (EGFR) to block cancer cell growth, and AZD1775, which targets the WEE1 kinase to make cancer cells more sensitive to DNA damage. This dual approach could potentially offer a novel way to treat cancers that are resistant to standard therapies.678910
Eligibility Criteria
Adults with advanced or metastatic solid tumors, such as non-small cell lung cancer or stomach cancers, who have had prior treatments but not in the first-line setting. Participants must be able to provide a tumor tissue sample and meet certain health criteria like good organ function and performance status.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive AZD7789 monotherapy in dose escalation cohorts to determine the maximum tolerated dose
Dose Expansion
Participants receive AZD7789 monotherapy in dose expansion cohorts to further evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AZD7789
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology